Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 3/20 | 0.47 |
| ▸ | CA4 known ✓ | P22748 | 5/20 | 0.41 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.35 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL106613 | 0.96 | CA1 (0.44) | CA1CA4FAHD1TSHRCYP3A4 | |
| Potassium Ion SCHEMBL21269002 | 0.96 | CA4 (0.47) | CA1CA4FAHD1TSHRCYP3A4 | |
| Lithium Ion SCHEMBL21269863 | 0.96 | CA1 (0.44) | CA1CA4FAHD1TSHRCYP3A4 | |
| SCHEMBL1582716 | 0.92 | CA1 (0.40) | CA1CA4FAHD1TSHRCYP3A4 | |
| SCHEMBL22042281 | 0.92 | CA1 (0.40) | CA1CA4FAHD1TSHRCYP3A4 | |
| SCHEMBL7618585 | 0.92 | CA1 (0.40) | CA1CA4FAHD1TSHRCYP3A4 | |
| SCHEMBL21268949 | 0.92 | CA1 (0.40) | CA1CA4FAHD1TSHRCYP3A4 | |
| SCHEMBL21269820 | 0.92 | CA1 (0.40) | CA1CA4FAHD1TSHRCYP3A4 | |
| Lithium Ion SCHEMBL105854 | 0.92 | CA1 (0.40) | CA1CA4FAHD1TSHRCYP3A4 | |
| SCHEMBL11587159 | 0.92 | CA1 (0.40) | CA1CA4FAHD1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256683-A1 | METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS | INDIAN OIL CORPORATION LIMITED (IN) | 2019-08-22 | — | — | US | claimed |
| EP-3527616-A1 | METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS | INDIAN OIL CORPORATION Ltd. (IN) | 2019-08-21 | — | — | EP | claimed |
| US-20160046582-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2016-02-18 | — | — | US | claimed |
| EP-2970129-A2 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | Teva Pharmaceutical Industries Ltd. (IL) | 2016-01-20 | — | — | EP | claimed |
| WO-2014153145-A2 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2014-09-25 | — | — | WO | claimed |
| EP-1878493-B1 | Method of making a polyisocyanurate/polyurethane foam using carbocation compounds as trimerization catalysts | AIR PROD & CHEM (US) | 2013-08-21 | — | — | EP | claimed |
| US-5756594-A | CATALYTIC POLYMERIZATION OF ALDEHYDE CARBOXYLATE MONOMER TO FORM POLYACETAL AND CROSSLINKING WITH POLYVINYL ETHERS, DIESTERS, DIEPOXIDES, ANHYDRIDES, DINITRILES AND DIACYL COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 1998-05-26 | — | — | US | claimed |
| WO-2024200617-A1 | PROCESS AND INTERMEDIATES FOR PREPARING A DRUG FOR THE TREATMENT OF UREA CYCLE DISORDERS | DIPHARMA FRANCIS S.R.L. (IT) | 2024-10-03 | — | — | WO | disclosed |
| EP-3527616-B1 | METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS | INDIAN OIL CORP LTD (IN) | 2024-02-07 | — | — | EP | disclosed |
| CN-109477829-B | Nuclear magnetic resonance analysis method for glycosaminoglycan, heparin and derivatives thereof | 罗维药物实验室股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-108475822-B | Nonaqueous electrolyte solution for secondary battery and secondary battery provided with same | 斯泰拉化工公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-110172019-B | Metal salts of malonic acid as nucleating additives for crystalline thermoplastics | 印度石油有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-11180630-B2 | Metal salts of malonic acid as nucleating additives for crystalline thermoplastics | INDIAN OIL CORPORATION LIMITED (IN) | 2021-11-23 | — | — | US | disclosed |
| US-4765825-A | PARTICULARLY EFFECTIVE AS PREEMERGENCE HERBICIDES FOR GRASSES | BUDAPESTI VEGYIMUVEK (HU) | 1988-08-23 | — | — | US | disclosed |
| US-4762919-A | STEROIDS | FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (US) | 1988-08-09 | — | — | US | disclosed |
| EP-0256095-A1 | ANTI-INFLAMMATORY CARBOXY PREGNANE DERIVATIVES. | UNIV FLORIDA AGRICULT MECH (US) | 1988-02-24 | — | — | EP | disclosed |
| WO-1987005028-A1 | ANTI-INFLAMMATORY CARBOXY PREGNANE DERIVATIVES | FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (US) | 1987-08-27 | — | — | WO | disclosed |
| US-4689423-A | Process for the preparation of 2,3,4,5-tetrafluorobenzoyl acetates | WARNER-LAMBERT COMPANY (US) | 1987-08-25 | — | — | US | disclosed |
| US-4643763-A | PLANT GROWTH REGULATORS | ICI AUSTRALIA LIMITED (AU) | 1987-02-17 | — | — | US | disclosed |
| EP-0181692-A2 | Cyclohexane-1,3-dione derivatives, compositions containing them, processes for making them, and their use as herbicides and plant growth regulators | ICI AUSTRALIA LIMITED (AU) | 1986-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256683-A1 | METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS | NUMA1, MNS1, ME1 | CA1 489/4885CA4 1318/4885CA2 478/4885 |
| US-11180630-B2 | Metal salts of malonic acid as nucleating additives for crystalline thermoplastics | NUMA1, MNS1, ME1 | CA1 489/4885CA4 1318/4885CA2 478/4885 |
| US-20160046582-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | HLA-DRB1, HAAO, RECQL | CA1 4305/4885CA4 1355/4885CA2 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.